ObjectiveTo evaluate the influence of interferon adjuvant therapy on immune parameters in postoperative patients with localized clear cell renal cell carcinoma (LCCRCC) and explore the related clinical significance. Methods Thirty-five patients with LCCRCC were treated with interferon α-2b hypodermic injection after surgery (6 MIU/time, three times per week for three months). Immune parameters, including CD4+,CD8+,CD4+/CD8+,CD16+56+,CD19+ , IL-2, IL-6, IL-10, IL-8, and TNF-α, were determined before and at the 1st , 2nd, 4th, 8th, and 16th week after therapy. And the results were compared before and after therapy. ResultsThree months after therapy, the levels of CD4+, CD8+ and CD4+/CD8+ were not significantly different from those before therapy. The of CD16+56+ was increased significantly during the first two weeks’ of treatment (P<0.05) and was significantly declined at the end of therapy (P<0.01). Compared with that before therapy, CD19+ levels were decreased in the 1st, 2nd and 4th week after treatment (all P<0.01), and was significantly increased at the 16th week (P<0.01). The level of IL-8 was significantly decreased at the 4th week after therapy (P<0.05) and TNF-α level was increased at the 8th week after therapy (P<0.01); the levels of other humoral immune parameters were not significantly different from those before therapy. Conclusion Treatment with interferon α-2b hypodermic injection (6 MIU/time, three times/week for three months) has a limited effect on promoting the immunity of patients with LCCRCC, and its influence on the long-term survival patients also needs further study.